

Malignant Pleural Mesothelioma Market Report 2032: Epidemiology Data, Therapies, Latest Approvals by DelveInsight

Malignant Pleural Mesothelioma companies are Sellas Life Sciences Group, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, and others.

LAS VEGAS, NEVADA, UNITED STATES, June 13, 2024 /EINPresswire.com/ -- DelveInsight's "Malignant Pleural Mesothelioma Market Insights, Epidemiology, and Market Forecast-2032" report offers an in-depth understanding of the Malignant Pleural Mesothelioma, historical and forecasted epidemiology as well as the Malignant Pleural Mesothelioma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.



Recent breakthroughs in the Malignant Pleural Mesothelioma Market:

In 2024, FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

In December 2022, Amphera released efficacy and safety data from the phase II/III DENIM trial in Mesothelioma.

Pegargiminase was granted Fast Track status by the US FDA for Mesothelioma in September 2022.

In June 2022, Momotaro-Gene completed enrollment in its phase II trial for Mesothelioma in the USA, focusing on combination therapy, late-stage disease, metastatic disease, and second-line therapy or greater, administered intratumorally.

In 2020, the U.S. Food and Drug Administration (FDA) approved the combination of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as a first-line treatment for adult patients with unresectable malignant pleural mesothelioma. This approval marks a significant advancement in the treatment options for this life-threatening cancer caused by inhaling

asbestos fibers.

In 2015, the US FDA awarded Orphan Drug Designation to MTG-201 for the treatment of malignant mesothelioma.

To Know in detail about the Malignant Pleural Mesothelioma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Malignant Pleural Mesothelioma Market Forecast](#)

Some of the key facts of the Malignant Pleural Mesothelioma Market Report:

The Malignant Pleural Mesothelioma market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

In 2021, the market for Malignant Pleural Mesothelioma (MPM) in the Seven Major Markets (7MM) was approximately USD 280 million.

Among the 7MM countries, the United States had the largest market size for MPM in 2021, totaling around USD 100 million.

Within the EU4 and the UK, the United Kingdom recorded the highest market size for MPM in 2021, amounting to approximately USD 46 million.

In Japan, the market size for MPM was observed to be approximately USD 39 million in 2021.

According to DelveInsight's projections for 2021, there were approximately 12,300 new cases of mesothelioma across the Seven Major Markets (7MM). Specifically, there were about 10,800 incident cases of Malignant Pleural Mesothelioma (MPM) in the same year within the 7MM.

In 2021, the United States accounted for roughly 17% of all Malignant Pleural Mesothelioma cases in the 7MM, totaling around 1,900 cases.

Within the 7MM, there were approximately 8,500 reported cases of MPM among males and about 2,400 cases among females in 2021.

The age group with the highest number of MPM cases in the 7MM was individuals aged 70-79 years, with approximately 4,000 cases reported in 2021.

Regarding specific types of mesothelioma within the 7MM in 2021, there were approximately 4,400 cases of Epithelioid type, 860 cases of Biphasic type, 880 cases of Sarcomatous type, and 4,700 cases classified as Mesothelioma NOS/NA.

In terms of stages, the distribution of MPM cases in the 7MM in 2021 was approximately 1,200 cases in Localized stage, 1,700 in Regional stage, 6,400 in Distant stage, and 1,500 in cases categorized as Unknown stage.

Key Malignant Pleural Mesothelioma Companies: Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, and others

Key Malignant Pleural Mesothelioma Therapies: Lurbinectedin, ONCOS-102, IMFINZI (durvalumab; MEDI4736), and others

The Malignant Pleural Mesothelioma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Malignant Pleural Mesothelioma pipeline products will significantly revolutionize the Malignant Pleural Mesothelioma market dynamics.

Malignant Pleural Mesothelioma Overview

Mesothelioma is a rare and aggressive cancer that forms in the lining of the lungs, abdomen, or heart. Exposure to asbestos is the sole known cause of this disease. Initial symptoms of mesothelioma mimic more common ailments like pneumonia, influenza, or irritable bowel syndrome. Due to its prolonged latency period, symptoms often manifest only after the cancer has advanced significantly. Diagnosis typically occurs following persistent coughing, pneumonia-like symptoms, or fluid accumulation, as mesothelioma can develop over decades without clear warning signs.

Mesothelioma is classified based on the location of tumor growth within the body. The most prevalent types include pleural mesothelioma (in the lungs), peritoneal mesothelioma (in the abdomen), pericardial mesothelioma (around the heart), and testicular mesothelioma, covering nearly all reported cases.

Malignant Pleural Mesothelioma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Malignant Pleural Mesothelioma Epidemiology Segmentation:

The Malignant Pleural Mesothelioma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Malignant Pleural Mesothelioma

Prevalent Cases of Malignant Pleural Mesothelioma by severity

Gender-specific Prevalence of Malignant Pleural Mesothelioma

Diagnosed Cases of Episodic and Chronic Malignant Pleural Mesothelioma

Download the report to understand which factors are driving Malignant Pleural Mesothelioma epidemiology trends @ [Malignant Pleural Mesothelioma Epidemiology Forecast](#)

Malignant Pleural Mesothelioma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Malignant Pleural Mesothelioma market or expected to get launched during the study period. The analysis covers Malignant Pleural Mesothelioma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid

uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Malignant Pleural Mesothelioma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Malignant Pleural Mesothelioma Emerging Drugs

IMFINZI (durvalumab; MEDI4736): AstraZeneca

ONCOS-102: AstraZeneca

Lurbinectedin: PharMar

Discover more about therapies set to grab major Malignant Pleural Mesothelioma market share @ [Malignant Pleural Mesothelioma Treatment Landscape](#)

Malignant Pleural Mesothelioma Market Outlook

Mesothelioma (MPM) is a rare tumor originating in the pleura, triggered by inhalation of asbestos fibers. It manifests in several types, including epithelial, sarcomatoid, and mixed/biphasic variants. Typically, the average life expectancy for pleural mesothelioma is less than 18 months, influenced by various factors such as cancer stage, patient age, and overall health.

Current treatment strategies for MPM encompass chemotherapy, radiation therapy, and surgical intervention. Multimodal therapy, a combination of these approaches, is often employed.

Surgery, particularly beneficial in early-stage diagnoses, aims to excise visible tumors, with subsequent chemotherapy and/or radiation targeting residual microscopic disease.

There are two primary surgical procedures for managing MPM: pleurectomy and decortication (P/D) and extrapleural pneumonectomy (EPP). These involve thoracotomy, an open chest incision. EPP, more aggressive but potentially more effective, entails removal of the pleura, affected lung, diaphragm, and pericardium. In contrast, P/D focuses on removing tumors and affected pleura while preserving the lung.

Malignant Pleural Mesothelioma Market Insights

In 2021, the market for Malignant Pleural Mesothelioma (MPM) in the Seven Major Markets (7MM) was approximately USD 280 million.

Among the 7MM countries, the United States had the largest market size for MPM in 2021, totaling around USD 100 million.

Within the EU4 and the UK, the United Kingdom recorded the highest market size for MPM in 2021, amounting to approximately USD 46 million.

In Japan, the market size for MPM was observed to be approximately USD 39 million in 2021.

Scope of the Malignant Pleural Mesothelioma Market Report:

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Malignant Pleural Mesothelioma Companies: Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, and others

Key Malignant Pleural Mesothelioma Therapies: Lurbinectedin, ONCOS-102, IMFINZI (durvalumab; MEDI4736), and others

Malignant Pleural Mesothelioma Therapeutic Assessment: Malignant Pleural Mesothelioma current marketed and Malignant Pleural Mesothelioma emerging therapies

Malignant Pleural Mesothelioma Market Dynamics: Malignant Pleural Mesothelioma market drivers and Malignant Pleural Mesothelioma market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Malignant Pleural Mesothelioma Unmet Needs, KOL's views, Analyst's views, Malignant Pleural Mesothelioma Market Access and Reimbursement

Table of Contents

1. Malignant Pleural Mesothelioma Market Report Introduction
2. Executive Summary for Malignant Pleural Mesothelioma
3. SWOT analysis of Malignant Pleural Mesothelioma
4. Malignant Pleural Mesothelioma Patient Share (%) Overview at a Glance
5. Malignant Pleural Mesothelioma Market Overview at a Glance
6. Malignant Pleural Mesothelioma Disease Background and Overview
7. Malignant Pleural Mesothelioma Epidemiology and Patient Population
8. Country-Specific Patient Population of Malignant Pleural Mesothelioma
9. Malignant Pleural Mesothelioma Current Treatment and Medical Practices
10. Malignant Pleural Mesothelioma Unmet Needs
11. Malignant Pleural Mesothelioma Emerging Therapies
12. Malignant Pleural Mesothelioma Market Outlook
13. Country-Wise Malignant Pleural Mesothelioma Market Analysis (2019–2032)
14. Malignant Pleural Mesothelioma Market Access and Reimbursement of Therapies
15. Malignant Pleural Mesothelioma Market Drivers
16. Malignant Pleural Mesothelioma Market Barriers
17. Malignant Pleural Mesothelioma Appendix
18. Malignant Pleural Mesothelioma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Malignant Pleural Mesothelioma Pipeline

"Malignant Pleural Mesothelioma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Malignant Pleural Mesothelioma market. A detailed picture of the Malignant Pleural Mesothelioma pipeline landscape is provided, which includes the disease overview and Malignant Pleural Mesothelioma treatment guidelines.

Malignant Pleural Mesothelioma Epidemiology

DelveInsight's 'Malignant Pleural Mesothelioma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Malignant Pleural Mesothelioma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Kritika Rehani
DelveInsight Business Research LLP
+1 469-945-7679
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/719720838>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.